SUPER Study; SUPERvised Exercise or Angioplasty for Intermittent Claudication Due to an Iliac Artery Obstruction. (SUPER)
SUPERvised Exercise Therapy (SET) or Immediate Percutaneous Transluminal Angioplasty (PTA) for Intermittent Claudication (IC) in Patients With an Iliac Artery Obstruction: A Randomized Controlled Trial. SUPER Study
The purpose of our study is to compare the clinical effectiveness and cost-effectiveness of two treatment strategies of Intermittent Claudication (IC) due to an iliac artery obstruction: to start with SUPERvised Exercise Therapy (SET) and deferred Percutaneous Transluminal Angioplasty (PTA) in case of SET failure, or immediate PTA.
It is our hypothesis that PTA as first line treatment is more effective than SET as first line treatment with regard to maximum walking distance, quality of life and costs after one year.
調査の概要
状態
詳細な説明
Intermittent claudication (IC) is a manifestation of cardiovascular disease, reflected by a threefold increased risk in these patients of developing serious cardiovascular events. Treatment of patients with IC is aimed at secondary prevention of cardiovascular events by control of risk factors for atherosclerotic disease, and to improve walking distance and subsequently quality of life. Supervised Exercise Therapy (SET) and Percutaneous Transluminal Angioplasty (PTA) can effectively improve pain free walking distance, but the optimal choice of treatment, specifically in patients with an iliac artery stenosis or occlusion is unclear. PTA is attractive as initial therapy since PTA of the iliac arteries has an immediate effect and it is durable. There is a lack of evidence from randomized controlled trials (RCT) to define the optimal treatment strategy for patients with IC due to iliac artery lesions; first line treatment with SET and PTA in case of failure, or immediate iliac artery PTA.
Purpose:
To define the optimal treatment strategy of IC due to an iliac artery obstruction: To start with SET and deferred PTA in case of SET failure, or immediate PTA.
Design:
Multicenter randomized controlled trial.
Patients:
400 patients with IC due to an iliac artery stenosis or occlusion.
Interventions:
SET and PTA.
Outcomes:
Primary outcomes are quality of life (Qol) recorded with the disease specific VascuQol instrument and maximum walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline after 1 year.
Secondary outcomes are pain-free walking distance, generic Qol, functional status, complications, number of treatment failures and costs. Economic evaluation comprises a cost-effectiveness and cost-utility analysis from a societal perspective, with the costs per patient able to walk maximal, respectively the costs per Quality Adjusted Life-Year (QALY) as outcome measures.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Almere、オランダ、1315 RA
- Flevoziekenhuis
-
Amsterdam、オランダ、1105 AZ
- Academic Medical Center
-
Amsterdam、オランダ、1091 AC
- Onze Lieve Vrouwe Gasthuis
-
Amsterdam、オランダ、1081 HV
- VU Medical Center
-
Amsterdam、オランダ、1061 AE
- Sint Lucas Andreas Ziekenhuis
-
Apeldoorn、オランダ、7334 DZ
- Gelre Ziekenhuizen
-
Arnhem、オランダ、6815 AD
- Ziekenhuis Rijnstate
-
Beverwijk、オランダ、1942 LE
- Rode Kruis Ziekenhuis
-
Deventer、オランダ、7416 SE
- Deventer Ziekenhuis
-
Haarlem、オランダ、2035 RC
- Kennemer Gasthuis
-
Hilversum、オランダ、1213 XZ
- Tergooiziekenhuizen
-
Hoofddorp、オランダ、2134 TM
- Spaarne Ziekenhuis
-
Nieuwegein、オランダ、3435 CM
- St Antonius Ziekenhuis
-
Nijmegen、オランダ、6525 GA
- UMC St. Radboud
-
Purmerend、オランダ、1441 RN
- Waterland Ziekenhuis
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 years or older;
- Disabling claudication as defined by surgeon based on patient's history;
- Ankle/Brachial Index (ABI) < 0.9 or drop in ABI > 0.15 after exercise test;
- Hemodynamic stenosis of the common or external iliac artery on Color Duplex Scanning (CDS) (PSV ratio ≥ 2.5 or EDV ≥ 0.6 m/s) or on Magnetic Resonance Angiography (MRA) or Computed Tomography Angiography (CTA)(> 50% stenosis) or occlusion of the common or external iliac artery on CDS (PSV 0 m/s) or on MRA or CTA;
- Iliac artery lesion and a concomitant stenosis in the superficial femoral artery defined as stenosis > 50% by CDS (PSV ratio ≥ 2.5 or EDV ≥ 0.6 m/s) or on MRA or CTA, or occlusion on CDS (PSV 0 m/s) or MRA or CTA;
- Lesion classified A, B or C according to the TASC (TransAtlantic Inter-Society Consensus) classification of aortoiliac lesions;
- Patient is able to walk at least 2 minutes on a treadmill at 3.2 km/h and 10% incline;
- The Maximum Walking Distance on a treadmill < 300 meters.
Exclusion Criteria:
- Life expectancy < 3 months;
- Patient is unable to complete self-reported questionnaires (insufficiently reading or speaking the Dutch language, cognitive disorders, etc);
- Patient is unable to give informed consent;
- A documented contrast allergy;
- Pregnancy;
- Contra-indication for anticoagulant therapy;
- Duration of current complaints < 3 months;
- Occlusion of the common femoral artery at the affected side;
- Patient participates in another study;
- Heart failure or Angina Pectoris NYHA III or IV. (NYHA III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea; NYHA IV: Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased);
- Patient previously received Supervised Exercise Therapy (SET) according to KNGF (Dutch Society for Physiotherapists) guidelines;
- Renal insufficiency (serum creatinin > 150 micromol/l).
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Intervention group: Angioplasty
Angioplasty with or without stent of the iliac artery
|
The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique.
A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected.
All PTA patients are encouraged perform at least three walking sessions every day.
他の名前：
|
|
アクティブコンパレータ：Control: Supervised Exercise Therapy
Supervised exercise therapy by a physiotherapist
|
Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists.
The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted).
The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities.
Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength.
All SET patients are encouraged to perform at least three walking sessions every day on their own.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease specific Quality of Life
時間枠：12 months
|
Disease specific Quality of life (Qol) recorded with the disease specific VascuQol instrument 1 year after intervention. The VascuQol will be completed at baseline and 1,6,12 months follow-up. |
12 months
|
|
Maximum Walking Distance
時間枠：12 months
|
Maximum walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline measured 1 year after intervention. The maximum walking distance will be assessed at baseline and 1,6,12 months follow-up. |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Painfree Walking Distance
時間枠：12 months
|
Painfree walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline 1 year after intervention. The painfree walking distance will be assessed at baseline and 1,6,12 months follow-up. |
12 months
|
|
Functional Status
時間枠：12 months
|
Functional status assessed by the AMC Linear Disability Score (ALDS) 1 year after intervention. The ALDS will be completed at baseline and 1,6,12 months follow-up. |
12 months
|
|
Generic Quality of Life
時間枠：12 months
|
Generic quality of life (Qol) recorded with the Short Form 36 (SF-36) and EQ-5D (former EuroQoL). The SF-36 will be completed at baseline and 1,6,12 months follow-up. The EQ-5D will be completed at baseline, 1 week and 1,6,12 months follow-up. |
12 months
|
|
Complications
時間枠：During 12 months
|
Complications related to both interventions during 12 months.
|
During 12 months
|
|
Treatment failures
時間枠：During 12 months
|
A treatment failure is defined as crossover to the other treatment arm.
|
During 12 months
|
|
Costs
時間枠：During 12 months
|
Costs during 1 year.
|
During 12 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Mark JW Koelemay, M.D., Ph.D、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- 主任研究者：Jim A Reekers, M.D., Ph.D.、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- 主任研究者：Dink A Legemate, M.D.,Ph.D.、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- スタディディレクター：Shandra Bipat, Ph.D.、Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
出版物と役立つリンク
一般刊行物
- Frans FA, Zagers MB, Jens S, Bipat S, Reekers JA, Koelemay MJ. The relationship of walking distances estimated by the patient, on the corridor and on a treadmill, and the Walking Impairment Questionnaire in intermittent claudication. J Vasc Surg. 2013 Mar;57(3):720-727.e1. doi: 10.1016/j.jvs.2012.09.044. Epub 2013 Jan 11.
- Frans FA, Bipat S, Reekers JA, Legemate DA, Koelemay MJ; SUPER Study Collaborators. SUPERvised exercise therapy or immediate PTA for intermittent claudication in patients with an iliac artery obstruction--a multicentre randomised controlled trial; SUPER study design and rationale. Eur J Vasc Endovasc Surg. 2012 Apr;43(4):466-71. doi: 10.1016/j.ejvs.2012.01.014. Epub 2012 Feb 10.
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。